Full Press Release Details
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 10, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company focused on cardiovascular disease today announced that it is scheduled to participate in two upcoming investor conferences: the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15, 2011 and the Citi 8th Annual U.S. Small/Mid Cap Conference also on Tuesday, November 15, 2011.
Joseph S. Zakrzewski, Chairman and Chief Executive Officer, is scheduled to present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15 at 10:00 a.m. EST. This conference will be held at The Pierre Hotel in New York City. A live audio webcast of the presentation will be available at: http://www.wsw.com/webcast/lz11/amrn/
John F. Thero, President, is scheduled to present at the Citi 8th Annual U.S. Small/Mid Cap Conference on Tuesday, November 15 at 3:05 p.m. PST. This conference will be held at the Four Seasons in Las Vegas. A live audio webcast of the presentation will be available at: http://www.veracast.com/webcasts/citigroup/smidcap2011/63113169.cfm
Amarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl). Amarin reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [>500 mg/dL]), as reported in November 2010, and the ANCHOR trial (investigation of AMR101 for the treatment of patients on statin therapy with high triglycerides [>200 and <500mg/dL] with mixed dyslipidemia), as reported in April 2011. Both the MARINE and ANCHOR trials were conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. In September 2011, Amarin submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of AMR101 for treatment of the patient population studied in the MARINE trial. Amarin plans to separately seek approval for the population studied in the ANCHOR trial after its REDUCE-IT cardiovascular outcomes trial is substantially underway. In August 2011, an SPA agreement with the FDA was reached for the REDUCE-IT cardiovascular outcomes study. The Company seeks to have this study substantially underway before the end of 2012.